BioMarin Posts Presentation From FDA Advisory Committee Meeting for Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Go back to BioMarin Posts Presentation From FDA Advisory Committee Meeting for Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 56.50 +0.60 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.90 | 52 Week High | $108.96 | |||
| Open | $55.80 | 52 Week Low | $62.12 | |||
| Day High | $57.00 | P/E | N/A | |||
| Day Low | $55.74 | EPS | $-1.27 | |||
| Volume | 1,987,924 | |||||
